Each week the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Pharmaceutical company Daiichi Sankyo made a $10m pledge yesterday to Hatch Biofund 1, a US-based venture capital fund formed by non-profit medical research organisation Baruch S. Blumberg Institute. Hatch Biofund has a $50m target for its close, and Daiichi Sankyo’s commitment was made in connection with a collaboration agreement with life sciences incubator Pennsylvania Biotechnology…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.